David A. Jacques

Allosteric capsid inhibitors and their escape mutants drive HIV-1 sensing

This study investigates allosteric capsid inhibitors and their resistance mutants, showing they trigger innate immune responses and may reduce HIV-1 transmission.

Mechanistic Insights into Lenacapavir-Induced Off-Pathway HIV-1 Capsid Assembly

This study uses molecular simulations to show that lenacapavir disrupts HIV-1 capsid assembly by altering hexamer/pentamer ratios and impairing RNA encapsidation.

The Human T-cell Leukemia Virus capsid protein is a potential drug target

The paper identifies a ligand-binding pocket in the HTLV-1 capsid protein essential for infectivity, suggesting it as a potential drug target for anti-capsid therapy.

Assessing the Validity of Leucine Zipper Constructs Predicted in AlphaFold2.

This study evaluates AlphaFold2 and AlphaFold-Multimer's ability to predict leucine zipper dimer interfaces in AP-1 transcription factors, revealing high confidence but potential inaccuracies.

Substrate-induced clustering activates Trim-Away of pathogens and proteins

This study reveals how substrate-induced clustering activates TRIM21's ubiquitination activity for antiviral responses and protein degradation, introducing optogenetically controllable TRIM21-nanobody chimeras.

SARS-CoV-2 proteases cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species and the search for reservoir hosts.

This study identifies SARS-CoV-2 proteases NSP3 and NSP5 cleaving IRF3, NLRP12, and TAB1, which modulate inflammatory pathways, and explores implications for disease across species and potential reservoir hosts.